EchoSolv AS vs VX1
AI Verdict
Choose EchoSolv AS if…
Choose EchoSolv AS if your cardiology department needs an efficient, AI-powered solution to accurately identify patients at high risk for severe aortic stenosis from existing echocardiogram measurements. This tool is ideal for streamlining workflow by providing consistent probability assessments and helping prioritize studies for closer review, without requiring EMR integration.
View EchoSolv AS →Choose VX1 if…
Choose VX1 if your electrophysiology lab seeks real-time AI guidance during atrial fibrillation and atrial tachycardia ablation procedures. This software is specifically designed to assist cardiologists in identifying dispersed electrograms, aiming to reduce inter-operator variability and standardize outcomes during complex EP interventions.
View VX1 →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | EchoSolv AS | VX1 |
|---|---|---|
| Pricing | Unknown | Contact for pricing |
| Deployment | Cloud-based | Software integrated with existing electrophysiology (EP) lab mapping and recording systems. |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
EchoSolv ASEchoSolv AS emphasizes minimal workflow disruption, explicitly stating 'no EMR integration required' and integration with PACS, alongside ultra-fast risk detection in under 3 seconds. This focus on simplified integration and rapid diagnostic review, leading to a 24.1% reduction in review time, gives it an edge in general usability for a broader range of cardiology practices.
Clinical Value
VX1While both are FDA-cleared and offer significant clinical value, VX1 directly assists cardiac electrophysiologists in real-time during complex ablation procedures, aiming to reduce inter-operator variability and standardize outcomes. Clinical trials have demonstrated high freedom from atrial fibrillation/atrial tachycardia after procedures, indicating a direct and measurable impact on procedural efficacy and consistency.
Pricing & Value
EchoSolv ASBoth tools require direct contact for pricing, indicating a lack of public transparency. However, EchoSolv AS has publicly disclosed its reimbursement strategy, including the identification of a miscellaneous CPT code (93799) and an expected reimbursement rate of US$100-US$150 per use, with Echo IQ receiving a portion of this. This provides more clarity on the potential economic value for adopting institutions compared to VX1's general 'contact for pricing' statement.
Enterprise Readiness
EchoSolv ASEchoSolv AS explicitly states HIPAA compliance, BAA availability, SOC 2, and ISO 27001 certifications, along with cloud-based deployment and PACS integration without requiring EMR integration. These explicit compliance claims and flexible deployment options make it demonstrably more enterprise-ready than VX1, which does not explicitly state BAA or HIPAA compliance in the provided information.
Innovation
VX1While EchoSolv AS employs innovative measurement-based AI for accurate AS detection, VX1's real-time, AI-guided assistance during complex interventional electrophysiology ablation procedures represents a more transformative application of AI in an immediate clinical workflow. It was the first FDA-cleared AI tool in interventional cardiac electrophysiology, directly impacting the execution and standardization of a highly operator-dependent procedure.
Support & Docs
TieBoth companies indicate the availability of user manuals and technical documentation. EchoSolv AS mentions providing documentation to assist with reimbursement processes, which is a practical form of support. However, without more specific details on the breadth, accessibility, or responsiveness of their general support channels, it is difficult to definitively distinguish between the two.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | EchoSolv AS | VX1 |
|---|---|---|
| Product Name | EchoSolv AS | VX1 |
| Company | Echo IQ | Volta Medical |
| Primary Clinical Focus | Identifying patients at risk for severe aortic stenosis (sAS) | Real-time identification of dispersed electrograms during atrial fibrillation and atrial tachycardia ablation procedures. |
| AI Analysis Method | Measurement-based AI (analyzes numerical measurements, not images); AI does not use LVOT measurements. | Analyzes 3D anatomical and electrical maps of human atria. |
| Integration | Designed to fit existing workflows (no EMR integration required, integrates with PACS) | Compatible with most EP recording, 3D navigation systems, and mapping catheters. |
| Key Benefit/Outcome | Accurate, quick, simple identification of high-probability severe AS patients; Ultra-fast risk detection (under 3 seconds). | AI-guided real-time identification of dispersed electrograms; Designed to reduce inter-operator variability and standardize outcomes. |
Videos
Demos, reviews, and walkthroughs featuring EchoSolv AS and VX1.